Hinge Bio is a privately held biotechnology company leveraging its powerful GEM-DIMER™ platform to develop therapeutics that address the problems of inadequate efficacy, resistance and side effects. The GEM-DIMER platform creates multivalent, multispecific antibody-based therapeutics that bind their targets in a novel manner allowing for dramatically enhanced biological activity and unique functionality. The GEM-DIMER technology was invented by Hinge Bio's Chief Scientific Officer, Daniel Capon, Ph.D., who previously was the first to clone and express recombinant Factor VIII (Genentech) and invented Fc-fusion proteins (Genentech) as well as chimeric antigen receptors for T cell therapy/CAR-T (Cell Genesys). Dr. Capon also holds patents on the XenoMouse for the production of fully human antibodies (Abgenix) and the PhenoSense drug susceptibility and resistance test (Monogram Biosciences/LabCorp).